ProJenX is a biotechnology company that originated from a collaboration between ALS research nonprofit Project ALS and researchers at Columbia University. The company focuses on developing treatments for ALS (Amyotrophic Lateral Sclerosis).

ProJenX

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines. 

We are very pleased to share this important milestone as we continue our mission to advance promising new therapies for ALS and other neurodegenerative diseases. In the coming weeks, we will initiate enrollment in participants with ALS in Canada, The Netherlands, and later this year, with sites in the United States.

Read the full release here: https://lnkd.in/gdMCkVm7

🎉 Exciting News! 🎉

ProJenX is thrilled to announce that we have received a $1M Hoffman ALS Clinical Trial Award from The ALS Association! This significant funding will accelerate our efforts in advancing prosetin in our Phase 1C study for ALS, bringing us one step closer to improving the lives of those affected by this challenging disease. Our team is deeply grateful for this support and remains committed to advancing cutting-edge research and clinical solutions. 

Stay tuned for more updates coming soon as we continue to make strides in the fight against ALS.

🔗 https://lnkd.in/e-DWkbJ3

#ALS #ClinicalTrials #MAP4K #MedicalResearch #Innovation #ProJenX #ALSAssociation #prosetin

ProJenX is excited to announce that study PRO-101 has been authorized in the European Union. Following Health Canada authorization in November, this second regulatory approval will allow us to expand the global footprint of this first-in-patient study of our lead candidate prosetin, a novel, CNS-penetrant MAP4K inhibitor for ALS, to participants in Europe. Read the press release here: 

https://lnkd.in/eiQ56ENb

#ALS #neurodegeneration

ProJenX is thrilled to announce the authorization of its clinical trial application (CTA) by Health Canada for the first-in-patient study of prosetin, a novel, CNS-penetrant MAP4K inhibitor developed for ALS. Read more here:
https://lnkd.in/eKb3KMpS

#ALS #neurodegeneration

Today, we are excited to announce the initial closing of our Series A financing and the appointment of Rick Hartz, Senior Vice President, Global Pharma & Human Health Business Development at Merck & Co, to our board of directors.
 
The ProJenX team would like to thank Medical Excellence Capital, LLC and our other investors for their ongoing support as we advance prosetin for people living with #ALS. We also look forward to working with Rick as we grow the company and expand our pipeline in neurodegeneration and other diseases with critical unmet needs.

https://lnkd.in/eSg2S6ic 

#braindiseases #neurodegeneration  #ALS #patientsfirst #biotech

COM:PROJENX

ProJenX

Financials Not Available